research Comparison of Therapeutic Efficacy of Topical Tacrolimus 0.1% and Topical Dithranol 0.5% in Treatment of Alopecia Areata
Dithranol is more effective than Tacrolimus for hair regrowth in alopecia areata.
Search
for
Sort by
Research
750-780 / 1000+ resultsresearch Editorial: Targeted immunological therapies in dermatology
Targeted immunological therapies offer safer and more effective treatments for skin conditions like eczema and psoriasis.
research Towards cell-based therapy of alopecia areata: Autologous human Vδ2+ Foxp3+ γδTreg cells restore hair-follicle immune privilege and promote hair regrowth in human alopecia areata models ex vivo and in vivo
Special cells can help regrow hair in alopecia areata.
research What's New: Newly Approved Drugs for Children
In 2001, the FDA approved 12 new drugs for children to treat allergies, asthma, ADHD, birth control, and other conditions.
research Delayed hypersensitivity reaction to intralesional triamcinolone acetonide following treatment for alopecia areata. Intradermal testing.
Intradermal testing can better detect corticosteroid allergies than patch testing.
research Recalcitrant lichen planopilaris and frontal fibrosing alopecia responding to tildrakizumab
Tildrakizumab significantly improved recalcitrant lichen planopilaris and frontal fibrosing alopecia.
research The Role of Antihistamines and Dupilumab in the Management of Alopecia Areata: A Systematic Review
Antihistamines may help with hair regrowth in alopecia areata, but dupilumab's effects are mixed.
research Interleukin‐1 family cytokines and soluble receptors in hidradenitis suppurativa
IL-18 levels are higher in hidradenitis suppurativa patients and may indicate disease severity.
research Dihydrotestosterone, and Not Testosterone, Enhances the LPS-Induced Inflammatory Cytokine Gene Expression in Human Adipocytes
Dihydrotestosterone boosts inflammation in fat cells more than testosterone.
research Triple Hormonal Blockade (ADT3): A Patient’s Perspective
Triple Hormonal Blockade (ADT3) can effectively manage prostate cancer but requires careful monitoring for heart risks.
research Human regulatory γδT lymphocytes as novel autoimmunity-protective cells: Lessons from alopecia areata
γδTregs may help treat autoimmune diseases like alopecia areata by promoting hair regrowth and reducing immune attacks.
research 218 Chemokine receptor CCR5 is the novel target for the treatment of alopecia areata
Blocking the CCR5 receptor may be a new way to treat hair loss from alopecia areata.
research T-cell “induced-self” MHC class I/peptide complexes may enable “de novo” tolerance induction to neo-antigens occurring outside of the thymus
Hair follicles may help teach the immune system to tolerate new self-antigens, but this can sometimes cause hair loss.
research Tumor necrosis factor inhibitors and janus kinase inhibitors in the treatment of cicatricial alopecia: A systematic review
Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.
research TRIAMCINOLONE ACETONIDE INTRAMUSCULARLY: EFFECTIVE LONG‐ACTING STEROID THERAPY IN DERMATOLOGIC DISORDERS
Triamcinolone acetonide injections effectively treat skin disorders like eczema and psoriasis.
research 15460 Perifollicular pink halo: A potential dermoscopic marker of inflammation in central centrifugal cicatricial alopecia
Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.
research Diverse Role of OX40 on T Cells as a Therapeutic Target for Skin Diseases
OX40-targeted therapies may help treat skin diseases by reducing inflammation and balancing immune responses.
research Therapeutic update on alopecia areata: a critical review of standard and emerging targeted therapies
research Topical immunomodulators in dermatology.
Topical immunomodulators are effective and safe for treating immune-related skin conditions.
research MAIT Cells in COVID-19: Heroes, Villains, or Both?
MAIT cells may help fight COVID-19 but also contribute to severe inflammation.
research Steroid 5α-reductase 2 deficiency leads to reduced dominance-related and impulse-control behaviors
Mice lacking steroid 5α-reductase 2 show less aggression and better impulse control.
research Clinical Snippets
Increased pigmentation may protect skin from UVB, new targets for skin disease treatments were identified, sunscreen ingredients don't affect hormones, TNF-α inhibitors may help diabetic wounds, and certain treatments could prevent chemotherapy-induced hair loss.
research Good efficacy achieved by telitacicept in treatment of systemic lupus erythematosus with alopecia areata
Telitacicept effectively improved hair regrowth in a woman with lupus and alopecia.
research Off-label dermatologic uses of IL-23 inhibitors
IL-23 inhibitors may help treat other skin conditions, but more research is needed.
research Resident T cell activation leads to human hair follicle immune privilege loss ex vivo, which is prevented by the DHODH inhibitor farudodstat: relevance for alopecia areata
Farudodstat may help prevent hair loss in alopecia areata by stopping immune attacks on hair follicles.
research In Silico Screening of DrugBank Compounds as Potential Inhibitors for Human Steroid 5α-Reductase 2 for Androgen-Related Diseases
Stiripentol shows promise as a potential treatment for androgen-related diseases but needs more testing.
research Conditional expression of the ErbB2 oncogene elicits reversible hyperplasia in stratified epithelia and up-regulation of TGFα expression in transgenic mice
research 860 Understanding cellular & molecular responses in the treatment of pediatric lymphatic anomalies
Sirolimus and propranolol may reduce abnormal cell growth and improve lymphatic malformations in children.
research Anti-acne drugs in phase 1 and 2 clinical trials
New anti-acne medications are being tested to offer alternatives to current treatments.
research 139 Anti-BCC efficacy of a topical hedgehog inhibitor without adverse effects in BCNS patients in a phase 2 randomized controlled trial
Topical patidegib gel effectively treats basal cell carcinoma in Gorlin syndrome patients without causing the side effects seen with oral treatments.